Confronta i metodi

	Saggio MTT/MTS	Saggio di emolisi
Campo	Biomateriali	Biomateriali
Famiglia	Process / pipeline	Process / pipeline
Anno di origine	1983	1950
Ideatore	Tatsuro Mosmann	Clinical hematology traditions
Tipo	Colorimetric assay	Hemolytic compatibility assay
Fonte seminale	Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63.	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.
Alias	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay	RBC lysis assay, hemolytic compatibility test, hemolytic potential test
Correlati	4	4
Sintesi	The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development.	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.